172 related articles for article (PubMed ID: 15550696)
21. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins.
Chen D; Riesbeck K; McVey JH; Kemball-Cook G; Tuddenham EG; Lechler RI; Dorling A
Xenotransplantation; 2001 Nov; 8(4):258-65. PubMed ID: 11737851
[TBL] [Abstract][Full Text] [Related]
22. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction.
Tousoulis D; Antoniades C; Bosinakou E; Kotsopoulou M; Tsoufis C; Marinou K; Charakida M; Stefanadi E; Vavuranakis M; Latsios G; Stefanadis C
Int J Cardiol; 2007 Feb; 115(2):203-7. PubMed ID: 16787670
[TBL] [Abstract][Full Text] [Related]
23. Factor Xa inhibits HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice.
Lee W; Ku SK; Bae JS
Thromb Haemost; 2014 Oct; 112(4):757-69. PubMed ID: 25007770
[TBL] [Abstract][Full Text] [Related]
24. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
[TBL] [Abstract][Full Text] [Related]
25. Activated partial thromboplastin time correlates with methoxyhydroxyphenylglycol in acute myocardial infarction patients: therapeutic implications for patients at cardiovascular risk.
Pinelli A; Trivulzio S; Rossoni G
In Vivo; 2014; 28(1):99-104. PubMed ID: 24425842
[TBL] [Abstract][Full Text] [Related]
26. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
27. Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction.
Balbay Y; Tikiz H; Baptiste RJ; Ayaz S; Saşmaz H; Korkmaz S
Angiology; 2001 Feb; 52(2):109-14. PubMed ID: 11228083
[TBL] [Abstract][Full Text] [Related]
28. Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects.
Holven KB; Aukrust P; Retterstol K; Hagve TA; Mørkrid L; Ose L; Nenseter MS
Scand J Clin Lab Invest; 2006; 66(1):45-54. PubMed ID: 16464786
[TBL] [Abstract][Full Text] [Related]
29. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells.
Damås JK; Otterdal K; Yndestad A; Aass H; Solum NO; Frøland SS; Simonsen S; Aukrust P; Andreassen AK
Circulation; 2004 Aug; 110(8):999-1005. PubMed ID: 15302794
[TBL] [Abstract][Full Text] [Related]
30. IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction.
Gabriel AS; Ahnve S; Wretlind B; Martinsson A
J Intern Med; 2000 Jul; 248(1):61-6. PubMed ID: 10947882
[TBL] [Abstract][Full Text] [Related]
31. The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina.
Wojakowski W; Maslankiewicz K; Ochala A; Wyderka R; Zuk-Popiolek I; Flak Z; Mroz I; Tendera M
Int J Mol Med; 2004 Aug; 14(2):317-22. PubMed ID: 15254785
[TBL] [Abstract][Full Text] [Related]
32. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction.
Merlini PA; Cugno M; Rossi ML; Agricola P; Repetto A; Fetiveau R; Diotallevi P; Canosi U; Mannucci PM; Ardissino D
Am J Cardiol; 2004 Apr; 93(7):822-5. PubMed ID: 15050482
[TBL] [Abstract][Full Text] [Related]
33. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Smith C; Halvorsen B; Otterdal K; Waehre T; Yndestad A; Fevang B; Sandberg WJ; Breland UM; Frøland SS; Oie E; Gullestad L; Damås JK; Aukrust P
Cardiovasc Res; 2008 Jul; 79(1):195-203. PubMed ID: 18339644
[TBL] [Abstract][Full Text] [Related]
34. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Bukowska A; Zacharias I; Weinert S; Skopp K; Hartmann C; Huth C; Goette A
Eur J Pharmacol; 2013 Oct; 718(1-3):114-23. PubMed ID: 24041930
[TBL] [Abstract][Full Text] [Related]
35. The proinflammatory cytokine response to coagulation and endotoxin in whole blood.
Johnson K; Aarden L; Choi Y; De Groot E; Creasey A
Blood; 1996 Jun; 87(12):5051-60. PubMed ID: 8652818
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
Akahane K; Okamoto K; Kikuchi M; Todoroki H; Higure A; Ohuchida T; Kitahara K; Takeda S; Itoh H; Ohsato K
Surgery; 2001 Nov; 130(5):809-18. PubMed ID: 11685190
[TBL] [Abstract][Full Text] [Related]
37. Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery disease.
Taylor AJ; Bobik A; Richards M; Kaye D; Raines G; Gould P; Jennings G
Am Heart J; 2004 Aug; 148(2):e10. PubMed ID: 15309013
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of coagulation activation and inflammation by a novel Factor Xa inhibitor synthesized from the earthworm Eisenia andrei.
Joo SS; Won TJ; Kim JS; Yoo YM; Tak ES; Park SY; Park HY; Hwang KW; Park SC; Lee DI
Biol Pharm Bull; 2009 Feb; 32(2):253-8. PubMed ID: 19182385
[TBL] [Abstract][Full Text] [Related]
39. Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute ST elevation myocardial infarction.
van der Pouw Kraan TC; Bernink FJ; Yildirim C; Koolwijk P; Baggen JM; Timmers L; Beek AM; Diamant M; Chen WJ; van Rossum AC; van Royen N; Horrevoets AJ; Appelman YE
J Mol Cell Cardiol; 2014 Feb; 67():94-102. PubMed ID: 24389343
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of naïve monocytes and PBMCs with coagulation proteases results in thrombin-mediated and PAR-1-dependent cytokine release and cell proliferation in PBMCs only.
Nieuwenhuizen L; Falkenburg WJ; Schutgens RE; Roosendaal G; van Veghel K; Biesma DH; Lafeber FP
Scand J Immunol; 2013 May; 77(5):339-49. PubMed ID: 23421536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
